Insights

Clinical Development Peel is advancing a clinical stage pipeline focused on cancer and inflammatory diseases. Sales teams offering clinical trial services, translational research, regulatory support, or clinical supply solutions may find a timely opportunity to support programs moving toward development milestones.

Recent Financing The company reported $36 million in seed financing, alongside more than $3 million in non dilutive funding. This capital may support near term research and development needs, creating potential demand for laboratory equipment, CRO services, specialized talent, and other biotech infrastructure.

Novel Therapeutics Peel designs medicines inspired by evolutionary biology, including neutrophil targeting peptides intended to address inflammation, immunothrombosis, and fibrosis. Providers of peptide engineering, formulation, bioavailability testing, or manufacturing scale up services could be relevant prospects.

Platform Expansion Company updates describe work on nanotechnology approaches for childhood cancer and drug development inspired by natural compounds. Vendors with expertise in drug delivery, oncology research, preclinical testing, or intellectual property and partnering support may have opportunities across these programs.

Lean Team With 11 to 50 employees and a broad drug development agenda, Peel may rely on external partners to extend internal capabilities. Business development teams can explore needs in outsourced research, cloud and data infrastructure, workflow software, and other services that help a compact biotech team operate efficiently.

Similar companies to Peel Therapeutics

Peel Therapeutics Tech Stack

Peel Therapeutics uses 8 technology products and services including Amazon Web Services, jsDelivr, Wix, and more. Explore Peel Therapeutics's tech stack below.

Media & News

Peel Therapeutics's Email Address Formats

Peel Therapeutics uses at least 1 email format:
Peel Therapeutics Email FormatsExamplePercentage
FLast@peeltx.comJDoe@peeltx.com
100%

Frequently Asked Questions

What is Peel Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Peel Therapeutics's official website is peeltx.com and has social profiles on LinkedIn.

How much revenue does Peel Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Peel Therapeutics's annual revenue is estimated to be $10M - $25M.

What is Peel Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Peel Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Peel Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Peel Therapeutics has approximately 12 employees across 2 continents, including North America and Asia. Key team members include Principal: J. M. Explore Peel Therapeutics's employee directory with LeadIQ.

What industry does Peel Therapeutics belong to?

Minus sign iconPlus sign icon
Peel Therapeutics operates in the Biotechnology Research industry.

What technology does Peel Therapeutics use?

Minus sign iconPlus sign icon
Peel Therapeutics's tech stack includes Amazon Web Services, jsDelivr, Wix, WordPress, Microsoft 365, OpenAI, Google Cloud and BugHerd.

What is Peel Therapeutics's email format?

Minus sign iconPlus sign icon
Peel Therapeutics's email format typically follows the pattern of FLast@peeltx.com. Find more Peel Therapeutics email formats with LeadIQ.

How much funding has Peel Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Peel Therapeutics has raised $25M in funding. The last funding round occurred on Feb 18, 2025.
Peel Therapeutics logo

Peel Therapeutics

Biotechnology ResearchUtah, United States11-50 Employees

Peel Therapeutics is a biotechnology research company based in Salt Lake City, Utah. It focuses on translating evolutionary outliers into medicines for cancer and inflammatory diseases, addressing solubility, scalability, and bioavailability in its clinical-stage pipeline. In April 2023, Peel Therapeutics announced the development of first-in-class neutrophil-targeting peptides derived from natural NET inhibitors found in newborns to block inflammation linked to immunothrombosis and fibrosis. The company appears to operate with a relatively small to mid-sized team within the biotechnology sector. Peel Therapeutics is positioned at the intersection of biology and drug development, pursuing therapies through biotech research methods.

Section iconCompany Overview

Website
peeltx.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $25M

    Peel Therapeutics has raised a total of $25M of funding over 7 rounds. Their latest funding round was raised on Feb 18, 2025 as a Series A.

  • $10M - $25M

    Peel Therapeutics's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.